The RBD‐CURE project will develop innovative gene therapy approaches for patients with rare bleeding disorders. The unique expertise of Sanquin on bleeding disorders together with the advanced gene therapy strategies developed by SanaGen and the Netherlands Institute for Neurosciences aims to provide a permanent cure for patients with rare bleeding disorders.
|Effective start/end date||1/10/2020 → 1/10/2023|
UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):